This story is just one example of the transformative possibilities that emerge when dedicated individuals and organizations unite to break down barriers in healthcare. Dr. Yehia and MRC team’s commitment to patient care and Eczacıbaşı-Monrol Nuclear Products contribution of Lutetium-177 doses underscore the collaborative success of the RLT-Platform, making a significant stride in accessible and advanced cancer care.
We look forward to witnessing more stories of hope and make Radiotheranostics options a reality.
Join our efforts to increase the number of patients that can benefit from this life-saving technology.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.